Skip to content

Study · Animal study (in vivo) · rat · 2019

3 results

Effect of Selank on Morphological Parameters of Rat Liver in Chronic Foot-Shock Stress.

Fomenko EV, Bobyntsev II, Ivanov AV, Belykh AE, Andreeva LA, Myasoedov NF

Bulletin of experimental biology and medicine26 Jun 2019Cited by 1 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats under chronic foot-shock stress, Selank at all doses reduced the intensity of stress-induced degenerative changes in the liver.

    In plain wordsIn rats under chronic foot-shock stress, Selank at every dose reduced stress-related damage to liver cells.

    Peptide
    Selank
    Outcome
    DecreaseStress-induced degenerative changes in the liver
    Study

    ratn: not reported in source

    Chronic foot-shock stress in Wistar male rats
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    100, 300 and 1000 μg/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    Injection of Selank in all doses reduced the intensity of stress-induced degenerative changes.
    2 context sentences
    Summary · context
    Selank was injected intraperitoneally in doses of 100, 300 and 1000 μg/kg 15 min before each stress session.
    Summary · context
    We studied the effects of Selank on morphological parameters of the liver in Wistar male rats subjected to chronic foot-shock stress.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats under chronic foot-shock stress, Selank at 300 and 1000 μg/kg restored the nucleus/cytoplasm ratio in hepatocytes.

    In plain wordsIn rats under chronic foot-shock stress, Selank at 300 and 1000 μg/kg brought liver cell nucleus size back toward normal.

    Peptide
    Selank
    Outcome
    DecreaseNucleus/cytoplasm ratio in hepatocytes
    Study

    ratn: not reported in source

    Chronic foot-shock stress in Wistar male rats
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    300 and 1000 μg/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    Administration of Selank in doses of 300 and 1000 μg/kg restored the nucleus/cytoplasm ratio in hepatocytes.
    2 context sentences
    Summary · context
    Morphological and morphometrical analysis showed that chronic foot-shock stress induced hydropic degeneration of hepatocytes, an increase of the nucleus/cytoplasm ratio due to an increase in the area of nuclei and reduction of the cytoplasm area, the appearance of focal necroses, and lymphohistiocyte infiltration.
    Summary · context
    We studied the effects of Selank on morphological parameters of the liver in Wistar male rats subjected to chronic foot-shock stress.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats under chronic foot-shock stress, the maximum stress-limiting effect on the liver was reached with Selank at 300 μg/kg.

    In plain wordsIn rats under chronic foot-shock stress, Selank at 300 μg/kg gave the strongest protection against stress in the liver.

    Peptide
    Selank
    Outcome
    DecreaseMaximum stress-limiting effect on the liver
    Study

    ratn: not reported in source

    Chronic foot-shock stress in Wistar male rats
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    300 μg/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    The maximum stress-limiting effect was attained after administration of 300 μg/kg Selank.
    1 context sentence
    Summary · context
    We studied the effects of Selank on morphological parameters of the liver in Wistar male rats subjected to chronic foot-shock stress.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.